Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation
Status:
Not yet recruiting
Trial end date:
2024-11-01
Target enrollment:
Participant gender:
Summary
The FDA approved targeted agent tazemetostat inhibits EZH2 and induces durable tumor
responses in patients with B-cell non-Hodgkin's lymphoma and epithelioid sarcomas. Responses
have also been demonstrated in INI1 and SMARCA4 negative solid tumors patients. Since EZH2
plays a critical role in driving the biology of ARID1A mutated malignancies, we hypothesize
that inhibition of EZH2 with tazemetostat will lead to significant clinical benefit in ARID1A
mutated malignancies.